Clinical Trials Browser

Phase 2 × INDUSTRY × Non-Small Cell Lung Cancer With EGFR Mutation × Clear all

NCT06668103 2024-12-12

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

Phase 2 Recruiting

Non-Small Cell Lung Cancer With EGFR Mutation